尖吻蝮蛇毒碱性磷脂酶A2的表达及其生化特征

将尖吻蝮蛇毒碱性磷脂酶A2 (A .aBPLA2 )基因克隆至温敏表达载体 pBLMVL2 ,在大肠杆菌RR1中成功诱导表达 .表达产物A .aBPLA2 约占细菌蛋白质总量的 2 0 % ,并以包涵体的形式存在 .纯化包涵体后 ,将产物变性、复性 ,然后用FPLCSuperoseTM12纯化 ,产物经过SDS 聚丙烯酰胺凝胶电泳检测只有单一条带 .对纯化后的表达A .aBPLA2 进行了酶活性、抑制血小板聚集活性和溶血活性的测定 .结果显示 ,表达A .aBPLA2的酶活性与变性后复性江浙蝮蛇酸性磷脂酶A2 酶活性相近 ,具有类似变性后复性江浙蝮蛇碱性磷脂酶A2 的溶血活性 ,没有抑制血小板聚集活性 .最后对磷脂酶A2 的结构与这些活性的关系进行了讨论     

尖吻蝮蛇毒酸性磷脂酶A_2Ⅱ的表达及其生化特征

将尖吻蝮蛇毒酸性磷酯酶 A2 ( A.a APLA2 )基因克隆至温敏表达载体 p BLMVL2 ,在大肠杆菌 RR1中成功诱导表达 .表达产物 A.a APLA2 约占细菌蛋白质总量 2 5 % ,并以包涵体形式存在 .纯化包涵体后 ,将产物变性、复性 ,然后用 FPLC Superose TM1 2纯化 ,产物经过 SDS- PAGE检测只有单一条带 .对纯化后的表达 A.a APLA2 进行了酶活性、抑制血小板聚集活性和溶血活性的测定 .结果显示 ,A.a APLA2 的酶活性处于变性后复性江浙蝮蛇酸性磷脂酶 A2 和碱性磷脂酶A2 的酶活性之间 ,没有抑制血小板聚集活性 ,只有微弱溶血活性 .最后对 PLA2 的结构与这些活性的关系进行了讨论     

尖吻蝮蛇毒碱性磷脂酶A2的表达及其生化特征

将尖吻蝮蛇毒碱性磷脂酶A₂（A.aBPLA₂）基因克隆至温敏表达载体pBLMVL2,在大肠杆菌RR1中成功诱导表达.表达产物A.aBPLA₂约占细菌蛋白质总量的20％,并以包涵体的形式存在.纯化包涵体后,将产物变性、复性,然后用FPLC Superose^TM12纯化,产物经过SDS-聚丙烯酰胺凝胶电泳检测只有单一条带.对纯化后的表达A.aBPLA₂进行了酶活性、抑制血小板聚集活性和溶血活性的测定.结果显示,表达A.aBPLA₂的酶活性与变性后复性江浙蝮蛇酸性磷脂酶A₂酶活性相近,具有类似变性后复性江浙蝮蛇碱性磷脂酶A₂的溶血活性,没有抑制血小板聚集活性.最后对磷脂酶A₂的结构与这些活性的关系进行了讨论.     

集成干扰素突变体IIFN72C的构建及其聚乙二醇定点修饰

目的：设计构建集成干扰素突变体IIFN72C并进行聚乙二醇定点修饰,以获得高活性的长效干扰素分子。方法：利用蛋白质分子同源模建,选择在集成干扰素分子IIFN的第72位引入半胱氨酸残基构成集成干扰素突变体IIFN72C。诱导表达后经包涵体变复性和层析纯化,与单甲氧基聚乙二醇（mPEGMAL）定点偶联。修饰产物经纯化后,以SDSPAGE考察其纯度,用WISHVSV系统进行生物活性测定。结果：IIFN72C以包涵体形式表达,表达量占菌体总蛋白的30%以上,比活性与突变前相当;修饰产物大多数为单修饰体,纯化后纯度大于98%,比活性保留约为修饰前的8%。结论：成功设计并表达IIFN72C用于PEG定点修饰,修饰产物活性保留得以提高。     

Gln49-磷脂酶A2基因工程定点突变及酶活性分析

为了确认49位谷氨酰胺磷脂酶A2（Glutamine 49 phospholipase A2, Gln49-PLA2）酶活性缺失与氨基酸序列的相关性,对Gln49-PLA2编码基因第49位氨基酸进行PCR定点突变,利用pET32a+质粒载体在大肠杆菌中表达Gln49-磷脂酶A2的突变体--天冬氨酸磷脂酶A2（Aspartic acid 49 phospholipase A2, Asp49-PLA2--Q49D-PLA2）。将表达的包涵体蛋白变性,采用固定化金属离子亲和层析进行柱上复性、纯化获得突变体融合蛋白（fusion Q49D-PLA2--fQ49D-PLA2）;突变体融合蛋白经蛋白水解酶Factor Xa酶切后,采用Hitrap SP阳离子交换层析和Superdex 75凝胶层析进一步纯化,得到突变体蛋白Q49D-PLA2,得率为1.3%,比酶活为72U/mg。从而证实Gln49-PLA2酶活性缺失的关键原因是49位氨基酸为谷氨酰胺。     

尖吻蝮蛇毒酸性磷脂酶A_2I的表达及其生化特征

将尖吻蝮蛇毒酸性磷脂酶 Ａ２ Ｉ（ Ａ．ａ Ａ Ｐ Ｌ Ａ２ Ｉ） 的基因克隆至表达载体ｐ Ｂ Ｌ Ｍ Ｖ Ｌ２ , 在大肠杆菌 Ｒ Ｒ１ 中成功表达。表达产物 Ａ．ａ Ａ Ｐ Ｌ Ａ２ Ｉ约占细菌蛋白质总量的３０ ％ , 以包含体的形式存在。纯化包含体后, 将产物变性、复性, 然后用 Ｆ Ｐ Ｌ Ｃ Ｓｕｐｅｒｏｓｅ Ｔ Ｍ１２ 纯化, 产物经过 Ｓ Ｄ Ｓ Ｐ Ａ Ｇ Ｅ 检测只有单一条带。对表达的 Ａ．ａ Ａ Ｐ Ｌ Ａ２ Ｉ进行了酶活性、抑制血小板聚集活性和溶血活性的测定。结果显示, 表达的 Ａ．ａ Ａ Ｐ Ｌ Ａ２ Ｉ的酶活性同变性后复性江浙蝮蛇酸性磷脂酶 Ａ２（ Ａ Ｐ Ｌ Ａ２） 的酶活性相近, 既具有抑制血小板聚集活性也具有溶血活性。最后对磷脂酶 Ａ２（ Ｐ Ｌ Ａ２） 的结构与这些活性的关系进行了讨论     

人巨细胞病毒M抗原表位保守氨基酸突变的分析

为确定人巨细胞病毒M抗原表位MAD的关键氨基酸残基, 以MAD多肽序列为基础, 分别将保守氨基酸残基单一突变为甘氨酸残基, 构建各自突变体, 然后与人源Fc的N端融合, 通过原核表达载体pET32-Fc表达融合蛋白MAD-Fc, 经protein A柱亲和纯化得到各突变体纯品。通过ELISA及Western blotting方法验证各突变体特异结合羊抗HCMV多抗间的差异, 从而确定表位关键氨基酸残基。结果显示, 将MAD中的谷氨酰胺残基单突变为甘氨酸残基后, MADQ-G结合羊抗HCMV多抗活性大大降低, 差异显著; 而其他氨基酸残基单突变时, 对MAD活性影响程度很小。由此得出结论: MAD结合羊抗HCMV多抗的活性与谷氨酰胺残基有关。     

大肠杆菌表达的重组人GM-CSF的纯化

本文对重组人粒细胞-巨噬细胞集落刺激因子(rhGM-CSF)高效表达克隆pZW.GM的表达产物进行纯化,并对纯化的人GM-CSF进行了N端氨基酸序列分析。人GM-CSF基因表达产物在大肠肝菌中以不溶性包涵体形式存在,经超声破菌、包涵体抽提、凝胶过滤层析、复性、离子交换一系列纯化步骤,终产物纯度达99％,按蛋白总量计算回收率达10％,比活性达1×10~7u/mg蛋白质。通过测定纯化人GM-CSF的N端16个氨基酸序列,与由其DNA序列推导的氨基酸序列完全一致。     

Sepharose 4B一步法对金环蛇蛇毒磷脂酶A2的分离纯化

利用经酸处理的Sepharose 4B为层析介质,以含0.2mol/L半乳糖,pH7.4台氏液作为洗脱液,从广西产金环蛇(Bungarus fasciatus)蛇毒中一步分离得到一种磷脂酶A2.用SDS-聚丙烯酰胺凝胶电泳测定其分子量为14 kDa.N端部分序列测定表明,所分离得到的磷脂酶A2其N端16个氨基酸残基序列与已报道的金环蛇蛇毒磷脂酶A2同功酶Ⅵ(Lu & Lo,1978)一致.该酶糖含量较高,为13.4%;具有弱的磷脂酶A2活性,无毒,也无溶血和出血毒活性.     

人骨形成蛋白-2C端102肽的诱骨活性

为分析更短的Hbmp-2C端肽是否具有诱骨活性 ,寻求新型的有诱骨活性的基因工程Hbmp-2产品。利用温度诱导的大肠杆菌表达系统表达肽段长度为102个氨基酸的Hbmp-2C端肽及其Cys的突变体。表达产物经纯化复性后 ,植入小鼠肌袋模型中测试其诱骨活性。获得了能稳定表达Hbmp 2C端肽的工程菌 ,测序结果与预期的序列完全一致。表达产物以包涵体形式存在 ,表达量占细胞总蛋白的 3 0 %。产物经纯化复性后 ,小鼠肌袋模型测试结果表明 :Hbmp 2 10 2肽仍具有诱骨活性 ,而将C端第一位Cys突变的 10 2肽诱骨活性丧失。实验表明 :比Hbmp 2成熟肽 ( 114个氨基酸 )更短的C端 10 2肽仍具有良好诱骨活性 ,这 10 2肽N端第一个Cys对其诱骨活性可能是必需的。     

Cloning, expression and biochemical characterization of a basic-acidic hybrid phospholipase A2-II from Agkistrodon halys pallas

A cDNA encoding a basic-acidic hybrid phospholipase A2-II from Agkistrodon halys Pallas with an N-terminus highly homologous to that of BPLA2 and a C-terminus sequence almost the same as that of APLA2 was inserted into a bacterial expression vector and effectively expressed in Escherichia coli RR1. The protein was produced as insoluble inclusion bodies. After partial purification by washing, the inclusion bodies with Triton X-100, denaturing and refolding, the renatured recombinant protein was purified by FPLC column superose 12. The purified recombinant enzyme with an isoelectric point of pH 6.8 could cross-react with antiserum prepared against acidic phospholipase A2. The enzymatic activity of the expressed basic-acidic hybrid phospholipase A2-II is close to that of denatured-refolded native basic phospholipase A2, and has the same inhibiting effect on platelet aggregation as denatured-refolded acidic phospholipase A2, but lacks the hemolytic activity of denatured-refolded basic phospholipase A2. To study the structural relationships among basic phospholipase A2, acidic phospholipase A2 and basic-acidic hybrid phospholipase A2-II, molecular modeling of basic-acidic hybrid phospholipase A2-II was done. The roles of various amino acid residues in the enzymatic activity and pharmacological activities of phospholipase A2 are discussed.     

抑瘤素-M(OSM)在GST融合表达系统中的表达、纯化和活性测定

抑瘤素Ｍ是一种具有多种生物活性的细胞因子,具有重要的研究价值和潜在的应用前景。基于ＧＳＴ融合表达载体,构建了一个ＯＳＭ的高效表达系统,诱导表达后融合蛋白占全菌蛋白的５０％以上,在低温诱导的条件下,可溶性蛋白中融合蛋白的含量可达１５％。在对包涵体形式的融合蛋白变复性的基础上,通过亲和层析一步纯化达到９０％左右的纯度。对融合蛋白进行了活性测定,结果提示了Ｎ端的头两个氨基酸对ＯＳＭ的生物活性是重要的。     

Expression of a group II phospholipase A2 from the venom of Agkistrodon piscivorus piscivorus in Escherichia coli: recovery and renaturation from bacterial inclusion bodies.

A synthetic gene encoding the Group II phospholipase A2 (PLA2) from the venom of Agkistrodon piscivorus piscivorus has been constructed and expressed with high efficiency in Escherichia coli. No enzymatic activity was recovered when the polypeptide contained the initiator Met residue. Replacement of an Asn residue penultimate to the initiator Met with Ser or Gly permitted removal of the initiator Met by the endogenous methionine aminopeptidase. The amino-terminal serine (N-Ser) and amino-terminal glycine PLA2's were isolated from intracellular inclusion bodies and were renatured with 25% recovery. Automated Edman degradation confirmed the removal of the initiator Met and confirmed the sequence of the first 40 residues of N-Ser PLA2. The recombinant proteins were purified to apparent homogeneity and showed the same specific activity as the wild-type protein. N-Ser PLA2 demonstrated the same kinetics of activation as the wild type enzyme on large vesicles of zwitterionic lipid.     

Renaturation of cobra venom phospholipase A2 expressed from a synthetic gene in Escherichia coli.

Cobra venom (Naja naja naja) phospholipase A2 (PLA2) contains 14 cysteines in the form of 7 disulfide bonds amongst its 119 amino acids. A gene encoding the PLA2 was synthesized and inserted into a bacterial expression vector containing the phage lambda pL promoter. In order to obtain protein without the initiating methionine at the N-terminus, a Factor Xa site was engineered upstream from the PLA2 gene. Upon heat-induction of the cells transformed with the expression plasmid, the protein is produced as insoluble inclusion bodies. The enzyme was partially purified by washing the inclusion bodies with Triton X-100 and urea. The expressed protein was first denatured with 8 M guanidine-HCl and 10 mM DTT. After digestion with Factor Xa, formation of disulfide bonds and refolding into the fully active form was carried out in the presence of cysteine and Ca2+. The renatured recombinant protein was purified by Affi-gel blue column chromatography. The purified recombinant enzyme had the same specific activity as the native enzyme when assayed on a variety of substrates and cross-reacted with antisera prepared against the native enzyme. This is the first report of the expression of a recombinant PLA2 from any venom.     

重组苦荞麦过敏蛋白TBa的原核表达及其免疫活性鉴定

TBa ［tartary buckwheat allergen］是苦荞麦中的一种主要过敏蛋白.根据长度为585 bp 的TBacDNA序列,以pET-28a为表达载体并选择合适的酶切位点合成上、下游引物,采用基因克隆技术构建重组表达载体pET-28a-TBa.进一步将重组质粒转入大肠杆菌BL21(DE3) 中进行表达.从而获得以包涵体形式存在的TBa目的蛋白.该目的蛋白经Ni ²⁺ -NTA琼脂糖柱亲和纯化及SDS-PAGE分析显示, 纯度达到95% 以上.用透析复性的方法将目的蛋白重折叠,其复性产率可达到约68%.Western印迹证实,目的蛋白N端带有6个组氨酸标签.ELISA检测表明,通过基因重组及表达获得的重组苦荞麦过敏蛋白,与天然苦荞种子中的该蛋白具有相似的免疫学活性,与荞麦过敏病人血清中的IgE有特异性的结合.     

Refolding and purification of non-fusion HPT protein expressed in Escherichia coli as inclusion bodies

The gene encoding hygromycin B phosphotransferase (hpt) is a widely used selectable marker in the production of genetically engineered crops. To facilitate the safety assessment of this protein, the non-fusion hpt expression plasmid was constructed and introduced into Escherichia coli to produce enough quantity of the HPT protein. High level expressed HPT was achieved but most of the expressed protein aggregated as inclusion bodies. The inclusion bodies were washed, separated from the cells, and solubilized by 0.3% Sarkosyl. The protein was renatured by dilution and dialysis, and then purified by anion-exchange chromatography. The activity is 8 U/mg protein and the purity is about 95%. Further studies showed that the microbially produced HPT protein had comparable molecular weight, immuno-reactivities, N-terminal amino acid sequences, and biological activities with those of the HPT produced by transgenic rice harboring hpt gene. All these results demonstrated the validity of utilizing the microbially produced HPT to assess the safety of the HPT protein produced in genetically engineered rice.     

Expression,purification, and characterization of recombinant lumbrokinase PI239 in Escherichia coli

Lumbrokinase (LK) is an important fibrinolytic enzyme derived from earthworms. It has been found that LK is composed of a group of isoenzymes. To construct and express the mature peptide of LK PI239 in Escherichia coli, we amplified and optimized the gene of LK which was then cloned into the prokaryotic expression vector pET-22b(?). The recombinant LK (rLK) protein was expressed as inclusion bodies and we have developed a purification process of rLK from these inclusion bodies. A step-down urea concentration strategy was applied to the rLK renaturation process. The purified and renatured rLK apparently ameliorated the conditions of the model thrombosis rats used, and may be developed into a therapeutic agent for thrombotic-associated diseases.